Premium
Lipid‐Modulating Treatments for Mixed Dyslipidemia Increase HDL‐Associated Phospholipase A 2 Activity with Differential Effects on HDL Subfractions
Author(s) -
Kei Anastazia,
Liberopoulos Evangelos,
Tellis Costantinos,
Elisaf Moses,
Tselepis Alexandros
Publication year - 2013
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/s11745-013-3826-y
Subject(s) - fenofibrate , rosuvastatin , dyslipidemia , medicine , lipoprotein associated phospholipase a2 , endocrinology , clinical chemistry , lipidology , high density lipoprotein , statin , cholesterol , chemistry , rosuvastatin calcium , lipoprotein , diabetes mellitus
The effect of lipid‐modulating treatments on modification of high density lipoprotein (HDL) subfractions remains unknown. In this study, mixed dyslipidemia patients ( n = 100) inadequately controlled with a standard statin dose were randomized to switch to 40 mg of rosuvastatin or add‐on extended release nicotinic acid/laropiprant (ER‐NA/LRPT) or add‐on fenofibrate. The cholesterol concentrations of HDL (HDL‐C) subfractions and HDL‐associated lipoprotein‐associated phospholipase A 2 (HDL‐Lp‐PLA 2 ) activity were assessed at baseline and 3 months later. We observed that large HDL‐C increased by 50 and 6 % in the add‐on‐ER‐NA/LRPT and rosuvastatin groups, respectively, while it decreased by 20 % in the add‐on‐fenofibrate group ( p < 0.01 vs baseline for all groups and p < 0.01 for all comparisons among groups). On the other hand, small HDL‐C decreased by 17 % in the add‐on‐ER‐NA/LRPT group ( p < 0.01 vs baseline), while it increased by 25 % in the add‐on‐fenofibrate group ( p < 0.01 vs baseline) without any change in the rosuvastatin group ( p < 0.01 for all comparisons among groups). HDL‐Lp‐PLA 2 activity increased by 55, 33 and 18 % in add‐on‐ER‐NA/LRPT, add‐on‐fenofibrate and rosuvastatin groups, respectively ( p < 0.01 for all comparisons vs baseline and for all comparisons among groups). In conclusion, add‐on‐ER‐NA/LRPT was associated with an increase in large HDL‐C and a decrease in small HDL‐C, while opposite effects were noticed in the add‐on‐fenofibrate group. Add‐on‐ER‐NA/LRPT was associated with the most pronounced increase in HDL‐Lp‐PLA 2 activity.